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Article abstract—Objective: To investigate the relationship between cigarette smoking and Alzheimer’s disease (AD) in a
prospective community-based study in northern Manhattan. Background: Results from previous case–control studies
suggest that there is a protective effect of smoking on AD. However, the recent prospective Rotterdam Study found that
there was an increased risk of AD for smokers, particularly those without an apolipoprotein E (APOE)-e4 allele. Methods:
The authors examined data from a community-based longitudinal study of local elders residing in northern Manhattan to
determine whether tobacco use increases or decreases the risk of AD. Information regarding the frequency of tobacco use
was obtained in structured interviews at the baseline assessment. Standardized clinical assessments were subsequently
completed on each subject at annual visits during which incident cases of AD were identified. Results: The relative risk
(RR) of AD among former smokers was 0.7 (95% CI, 0.5 to 1.1). The RR among current smokers was 1.9 (95% CI, 1.2 to
3.0). Smokers without an APOE-e4 allele had the highest risk of AD (RR 5 2.1; 95% CI, 2.1 to 3.7) compared with those
with an APOE-e4 allele (RR 5 1.4; 95% CI, 0.6 to 3.3). Conclusions: Our results are consistent with the observation that
smoking increases the risk of AD. However, we found that among previous smokers who quit smoking, there may be a
slight reduction in the risk of AD.
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It has been proposed that smoking augments cholin-
ergic metabolism by upregulation of cholinergic nico-
tinic receptors in the brain.1 Many of the man-
ifestations of Alzheimer’s disease (AD) are attributed
to alterations in acetylcholine metabolism2-4 and as a
result, smoking was thought to decrease the risk or
at least retard the onset of symptoms associated
with AD through this mechanism.
Methodological limitations of previous case–control
studies5-7 have generated interest in conducting pro-
spective studies to examine the relationship between
smoking and AD. A recent study from The Nether-
lands examined the association of cigarette smoking
with dementia and AD.8 Their results show that in
comparison with those who never smoked, smokers
had a twofold increase risk of dementia and AD.
In our prospective community-based study, we ex-
amined data collected prospectively from elders re-
siding in northern Manhattan. We postulated that
the risk of AD would be elevated among current
smokers compared with past smokers or those who
do not have a smoking history. Recognizing the link
between apolipoprotein E (APOE)-e4 and AD,9-11 we
posited that the e4 allele might effect the association
between smoking and AD risk.
Methods. Setting and participants. Data were ana-
lyzed from a sample of Medicare recipients in three contig-
uous zip codes within the community of Washington
Heights in northern Manhattan, New York City.
A total of 2,128 persons participated in the initial phase
of the study. A 90-minute, in-person interview of general
health and function was completed. This structured inter-
view also included questions about years of formal educa-
tion. The interview was followed by a standardized clinical
assessment including a medical history, physical and neu-
rologic examination, and a brief (approximately 1 hour)
neuropsychological battery developed previously for use in
this community.12,13 These same clinical assessments were
used in the annual follow-up of all participants. The inter-
views were conducted in either English or Spanish. The
Columbia University Institutional Review Board reviewed
and approved this project. All participants provided writ-
ten informed consent.
For this study data were excluded from 290 people
(13.6%) who were found demented at the initial interview
(using the methods described), 349 (16.4%) who refused
subsequent follow-up, 155 (7%) who died after the initial
examination, 129 (6.1%) missing smoking information, 25
(1.2%) individuals with PD, 117 (5.5%) with stroke, and 1
individual with both PD and stroke. All data from the
remaining 1,062 elderly (730 women and 352 men) without
dementia were considered appropriate for the investiga-
tion. Annual follow-up examinations were conducted over
an average of 2.04 years.
AD diagnosis. All participants were examined by a
neurologist or an appropriately trained internist or psychi-
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atrist, and all underwent neuropsychological testing. The
data from the initial and follow-up examinations and inter-
views, and any existing medical records and imaging stud-
ies were reviewed collectively at a consensus conference of
physicians and neuropsychologists to establish diagnoses.
Clinicians were unaware of the APOE genotype during the
diagnostic process. The diagnosis of dementia or the spe-
cific clinical diagnosis of AD was based on specified re-
search criteria14,15 and required evidence of cognitive
deficit on clinical evaluation in addition to objective neuro-
psychological findings, as well as evidence of impairment
in social or occupational function. Patients meeting crite-
ria14 for probable or possible AD with a Clinical Dementia
Rating16 score of 1.0 or higher were considered to have the
clinical diagnosis of AD. To exclude the diagnosis of mixed
dementia (i.e., AD and vascular dementia), cerebrovascu-
lar disease was identified by a clinical history of stroke or
TIA, or by evidence of cerebrovascular lesions on brain
imaging. All those with any history of cerebrovascular dis-
ease or mixed dementia were excluded from the study.
Ethnic group. For ethnic group classification we used
the format suggested by the 1990 United States Census
Bureau.17 In the first question, participants were asked to
which ethnic group they belonged. The possible responses
included white, black (African American or Caribbean
American), American Indian, Asian, or other. Regardless
of the response, a second question asked whether or not
the person being interviewed considered him or herself
Hispanic. Several choices were then provided to indicate
specific Hispanic origin (e.g., Puerto Rico, Dominican Re-
public, Cuba). Each individual was also asked to identify
the country of their birthplace. For this study, we used the
categories of black (non-Hispanic), white (non-Hispanic),
and Hispanic consistent with the census data.
Risk factor interview. A structured risk factor ques-
tionnaire was developed for the assessment of exposures to
putative risk factors related to dementia.18 The interviews
were given in English and Spanish according to the prefer-
ence of the patient.
For smoking there were three sets of questions. A trig-
ger question asked whether or not the individual ever
smoked at least one cigarette per day for a period of 1 year
or more. If the answer was no, no further questions were
asked. If the subject answered yes, the individual was
asked at what age they began smoking, whether they were
still smoking, at what age they had stopped if no longer
smoking, and how many cigarettes on average they had
smoked or still smoked per day.
The two other sets of smoking questions asked about
cigar and pipe use. Both began with a trigger question
asking whether the individual had ever smoked a cigar or
pipe. If the subject answered no, no further questions were
asked. If the subject answered yes, follow-up questions
similar to those for cigarettes were asked but referred to
the number of cigars or pipe-fulls smoked daily.
A composite vascular “heart” disease variable was for-
mulated to assess whether cardiac disease may act as a
possible confounder of AD. The vascular disease variable
included anyone reporting a history of myocardial infarc-
tion, congestive heart failure, angina, and anyone taking
cardiac medication.
APOE genotyping. The APOE genotype for each par-
ticipant was determined after isolating DNA from white
blood cells and digesting the DNA with HhaI.19 Leukocyte
DNA was amplified by PCR using specifically synthesized
oligonucleotide primers and Taq polymerase modified from
those described by Hixson and others.20,21 The digested
PCR fragments were then separated by electrophoresis.
Data analysis. The frequencies for each demographic
variable (age, gender, education, and ethnic group) and for
smoking were compared among those at-risk participants
and those with AD using chi-square analyses and Fisher’s
exact tests.22
Risk ratio estimates were calculated to assess the rela-
tionship between AD and smoking, in addition to other
demographic variables. Univariate measures of association
were estimated from chi-square analysis. Multivariate risk
ratios were estimated from Cox proportional hazard mod-
els for each risk factor.23 As recommended by Korn et al.,23
the time-to-event variable was the age at onset of AD;
therefore, no further age adjustment was required. The
first stage of assessment included only smoking history.
We then included education, and the final model included
education in addition to ethnicity, and APOE genotype.
This information was used to identify differences with re-
spect to education and ethnic group identity represented in
the community.
Results. Demographics. Table 1 shows the demo-
graphic characteristics of the study participants by AD and
nondemented control subjects. Obvious group differences
were apparent for age at interview and education. Patients
with AD were significantly older than the control subjects
(x2 5 25.0, p , 0.001) and had the least amount of formal
education (x2 5 26.4, p , 0.001), whereas patients with
AD were very similar to control subjects in ethnic group
representation and smoking status.
Reliability. The test–retest reliability18 of the risk fac-
tor interview was in the good to excellent range for the
questions regarding smoking (k 5 0.72).
Smoking. The frequency of smoking varied signifi-
cantly by age and gender, but not by ethnic group or edu-
cation (table 2). Smoking decreased with age, and varied
by sex in that more women reported that they never
Table 1 Demographic profile of population-based study
Characteristics Alzheimer’s disease Total at risk
n 142 920
Women, n (%) 99 (69.7) 631 (68.6)
Age, y (SD) 77.2 (5.7)* 75.1 (6.2)
Education, y (SD) 7.1 (3.8)* 9.0 (4.5)
Ethnic group, n (%)
African American 57 (40.1) 291 (31.6)
White 21 (14.8) 238 (25.9)
Hispanic 62 (43.7) 386 (42.0)
Smoking status, n (%)
Never 79 (55.6) 451 (49.0)
Past 36 (25.4) 325 (35.3)
Current 27 (19.0) 144 (15.7)
* Indicates significant difference from the total at-risk group
based on chi-square analysis.
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smoked. There was no difference in tobacco use across
ethnic groups. The majority of smokers were cigarette
smokers. Only four patients with AD and five nonde-
mented subjects restricted their smoking to cigars or a
pipe. A few in each group smoked cigars or a pipe as well
as cigarettes according to our definition. We did not per-
form separate analyses for those who use only cigars or
pipes because these were relatively infrequent as expo-
sures. However, we did include cigar and pipe smokers in
comparing smokers with nonsmokers. Among those who
quit smoking, the mean time since cessation was 21.4
years. Because it was possible that smoking might have
delayed or hastened the onset of AD, we compared the age
at onset of symptoms between smokers and nonsmokers
with AD. The mean age at onset of symptoms for smokers
with AD was significantly lower than for nonsmokers
(nonsmokers, 80.9 6 5.9 versus smokers, 76.5 6 4.9;
p , 0.001).
Alzheimer’s disease. Although there were no statisti-
cally significant differences in the risk of developing AD
between current smokers, past smokers, and those who
reported never smoking on univariate analysis (x2 5 5.5,
p , 0.06), there were slightly more current smokers among
the subjects (see table 1). Multivariate analysis showed
that a past history of smoking was not associated signifi-
cantly with AD (relative risk @RR# 5 0.7; 95% CI, 0.5 to
1.1). However, those who were current smokers had an
increased risk of developing AD as indicated by the unad-
justed RRs and CIs in table 3 (RR 5 1.9; 95% CI, 1.2 to
3.0). Adjustment for education and ethnicity did not alter
the measure of association between smoking and AD
(RR 5 1.7; 95% CI, 1.1 to 2.8). The association between
smoking and AD was slightly lowered in the presence of
APOE-e4 (RR 5 1.4; 95% CI, 0.6 to 3.3; table 4), but not for
current smokers without APOE-e4 (RR 5 2.1; 95% CI, 1.2
to 3.7). Table 5 lists the distribution of smoking history by
AD status, APOE status, and age group.
After reviewing these results additional questions arose
concerning vascular disease acting as a possible con-
founder. Smoking is a risk factor for vascular disease. Car-
diac disease increases the risk of vascular dementia.
Therefore, we looked at two additional multivariate models
(multiplicative and additive) to determine the likelihood of
interaction. The multiplicative proportional hazard model
included ethnic group, smoking history, and a composite
vascular “heart” disease variable. In the multiplicative
model there was no evidence of interaction among those
who were both current smokers and had cardiac disease
(current smokers: RR 5 1.9; 95% CI, 1.1 to 3.3; heart
disease: RR 5 1.1; 95% CI, 0.72 to 1.78; current smokers 3
heart disease: RR 5 1.1; 95% CI, 0.4 to 3.2). In the additive
model, which included all of the variables just listed, there
was the suggestion of interaction among those who were
both current smokers and had cardiac disease (current
smokers: RR 5 1.9; 95% CI, 1.1 to 3.3; heart disease: RR 5
1.1; 95% CI, 0.7 to 1.8; current smokers and heart disease:
RR 5 2.4; 95% CI, 0.97 to 5.7). However, the number of
individuals in this group was small (n 5 14), thus limiting
the interpretation. Finally, stratification by heart disease
did not alter the relationship between smoking and AD in
those with and without APOE-e4.






65–74 648 117 (68.4) 239 (66.2) 292 (55.1)
75–84 334 49 (28.7) 99 (27.4) 186 (35.1)
851 80 5 (2.9)* 23 (6.4) 52 (9.8)
Gender
Women 730 89 (52.0) 204 (56.5) 437 (82.5)
Men 332 82 (48.0) 157 (43.5) 93 (17.5)*
Education, y†
0–7 356 68 (40.0) 121 (33.8) 167 (31.7)
8–11 287 42 (24.7) 94 (26.3) 151 (28.7)
121 412 60 (35.3) 143 (39.9) 209 (39.7)
Ethnicity‡
African American 348 74 (44.3) 117 (32.4) 157 (29.8)
White 259 35 (21.0) 92 (25.5) 132 (25.0)
Hispanic 448 58 (34.7) 152 (42.1) 238 (45.2)
* Denotes a significant difference from the comparison groups in
the same category based on chi-square analysis.
† Owing to missing data on educational profile, seven partici-
pants were omitted.
‡ There were seven participants who failed to classify themselves
as either white, African American, or Hispanic.
Table 3 Relative risk estimates for smoking in AD
Tobacco use
Total at




Never 672 79 (11.8) 1.0 reference 1.0 reference
Past 361 36 (9.9) 0.8 [0.5–1.1] 0.7 [0.5–1.1]
Current 171 27 (15.8) 1.9 [1.2–3.0] 1.7 [1.1–2.8]
* Multivariate analysis adjusted for education and ethnicity.












Never 118 24 (20.3) 1.0 reference*
Past 103 14 (13.6) 0.8 [0.4–1.5]




Never 336 52 (15.5) 1.0 reference*
Past 210 18 (8.6) 0.6 [0.3–1.1]
Current 100 18 (18.0) 2.1 [1.2–3.7]
* Multivariate analysis adjusted for education and ethnicity.
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Discussion. The results of this prospective study
demonstrate that current smokers had a slightly
higher risk of AD. The recent Rotterdam Study
examined the effect of smoking on dementia and
AD.8 Their results show that in comparison with
those who never smoked, smokers had an increased
risk of dementia (RR 5 2.2; 95% CI, 1.3 to 3.6) and
AD (RR 5 2.3; 95% CI, 1.3 to 4.1). Our results are
consistent with the Rotterdam Study findings in this
respect. Complementary results were also found
with respect to the effect modification role of APOE-
e4. Results from the Rotterdam Study show that
smokers who were not carriers of the APOE-e4 allele
had a fourfold increased RR of AD (RR 5 4.6; 95%
CI, 1.5 to 14.2).
Arguments have been posed to explain the rela-
tionship between smoking and AD. These discus-
sions have focused on previous case–control studies
reporting a lower risk for AD associated with smok-
ing. Several authors have argued that this protective
association may have been related to differential sur-
vival based on genetic alterations.6,24-26 A similar ar-
gument could be made for our finding among those
who quit smoking. There was a suggestion of a pro-
tective effect among those who quit smoking. This
raises the question of whether those smokers who
survived without encountering comorbid conditions
(such as cardiovascular disease) commonly associ-
ated with tobacco use, who then quit smoking, may
have acquired some additional protection, reducing
their susceptibility to AD. The capacity of cells to
repair DNA declines with age, and is adversely al-
tered with smoking.26-28 Therefore, those surviving
former smokers may have more effective DNA repair
mechanisms. As a consequence, the accumulation of
aging-associated defects in DNA and DNA repair,
which are presumed to be associated with AD,29 may
be altered among surviving former smokers, reduc-
ing their susceptibility to AD.
Our study demonstrates that APOE-e4 only
slightly modifies the association between smoking
and AD (RR overall 5 1.9 verses RR without e4 5
2.1). The link between smoking, AD, and APOE ge-
notype is controversial. From the Rotterdam Study,
Van Duijn et al.10 and Ott et al.8 both demonstrated
that APOE-e4 had a pronounced effect in patients
with AD. Their findings suggest that there is an
increased risk of dementia and AD associated with
smoking in those without the APOE-e4 allele. How-
ever, due to the disproportional mortality rates be-
tween smokers and nonsmokers who are APOE-e4
carriers, the question remains whether there are ad-
ditional factors in the causal chain possibly related
to vascular disease. The results of our study failed to
show any significant interaction between smoking,
vascular disease, and AD or smoking, vascular dis-
ease, AD, and APOE. However, an acute effect of cig-
arette smoking is a reduction in cerebral perfusion.30
This poses a crucial threat to elders with existing cere-
brovascular compromise. Smoking has also been linked
to an increased risk of premature death.31
Ethnicity and educational attainment are recog-
nized correlates of smoking, and both have been
linked to AD.31,32 After adjusting for these variables
in the multivariate analysis, the smoking-associated
risk of AD did not change. There was no proportional
difference in tobacco use across ethnic groups. Both
ethnicity and education may be considered proxies
for various factors associated with socioeconomic
status and health-related behavior. According to a
recent review of smoking behavior across ethnicity and
socioeconomic status, less educated African Americans
were more likely to smoke compared with whites or
Hispanics.32 Furthermore, African Americans were
less likely to quit smoking than whites or Hispan-
ics.32 Based on the findings of our comparative study,
from a public health standpoint, equal emphasis
should be placed on smoking cessation programs
across ethnic groups and regardless of socioeconomic
status among the elderly.
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